NCT06624189Enrolling by invitation
Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis
Active Choice Clinical Decision Support: Hepatocellular Carcinoma Screening in Patients With Cirrhosis
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
The research team will evaluate the effectiveness of an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 1300 (estimated)
- First submitted
- 1 Oct 2024
- Start date
- 20 Nov 2024
- Primary completion date
- 24 Apr 2026
- Lead sponsor
- NYU Langone Health
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06624189
What you commit to
- Study type: Observational
- Planned participants: 1300
- From 20 Nov 2024 to the primary completion date, 24 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous liver transplant,
- receiving hospice care,
Other
- HCC diagnosis,
- completed external imaging in the past 6 months.
Who the study is looking for
- cirrhosis diagnosis,
- 6 months or more after since most recent imaging.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYU Langone Health Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.